ALRESTATIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H9NO4
Molecular Weight	255.2256
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)CN1C(=O)C2=CC=CC3=CC=CC(C1=O)=C23

InChI

InChIKey=GCUCIFQCGJIRNT-UHFFFAOYSA-N

InChI=1S/C14H9NO4/c16-11(17)7-15-13(18)9-5-1-3-8-4-2-6-10(12(8)9)14(15)19/h1-6H,7H2,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C14H9NO4
Molecular Weight	255.2256
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8003482 | https://www.ncbi.nlm.nih.gov/pubmed/8329799

Alrestatin, an inhibitor of aldose reductase, was studied in clinical trials for the treatment of diabetes. But this study was discontinued, because of the high hepatotoxicity events.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Aldose reductase 45 Target ID: P15121 Gene ID: 231.0 Gene Symbol: AKR1B1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8003482	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Diabetes mellitus 93 Sources: https://www.ncbi.nlm.nih.gov/pubmed/122298	Primary		Withdrawn	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Diabetic cataract-pathogenesis, epidemiology and treatment.	2010	20634936
Advances in pharmacological strategies for the prevention of cataract development.	2009-04-23	19384010
Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells.	2007-08-31	17626897
Upregulation of aldose reductase by homocysteine in type II alveolar epithelial cells.	2005-12-02	16225842
Proteomic analysis of oxidative stress-resistant cells: a specific role for aldose reductase overexpression in cytoprotection.	2004-02	14676331
Neonicotinoid insecticides: reduction and cleavage of imidacloprid nitroimine substituent by liver microsomal and cytosolic enzymes.	2002-09	12230409
Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes.	2001-07	11461193

Sample Use Guides

In Vivo Use Guide

diabetic patients with severe peripheral neuropathy: intravenously (50 mg/kg body weight); orally (1 gm q.i.d.)

Route of Administration: Other

In Vitro Use Guide

Alrestatin (10 uM) attenuated the effect of high glucose (HG) to increase angiotensin (Ang) II accumulation in cells and media and decrease the Ang I level in media. The partial inhibitory effect of alrestatin could be attributable to posttranscriptional modification of aldose reductase such as S-thiolation, which makes this enzyme less sensitive to inhibitors.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:06 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:06 GMT 2025`
Record UNII	515DHK15LG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

NSC-299132

Preferred Name

English

ALRESTATIN

Official Name

English

Alrestatin [WHO-DD]

Common Name

English

alrestatin [INN]

Common Name

English

1,3-DIOXO-1H-BENZ(DE)ISOQUINOLINE-2(3H)-ACETATE

Systematic Name

English

1H-BENZ(DE)ISOQUINOLINE-2(3H)ACETIC ACID, 1,3-DIOXO-

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C72880